Pharmaceutical Suspension
| Strength | 25 mg/mL |
| Packaging Size | 8ml |
| Brand | Survanta |
| Also gives | PCD Pharma |
| Shelf life | 24 Months |
| Usage | Anti Cancer |
8 ml Beractant intratracheal suspension is a surfactant therapy used primarily for the treatment of neonatal respiratory distress syndrome (RDS) in premature infants. Beractant is derived from animal lung surfactant and works by reducing surface tension in the alveoli, improving lung compliance and oxygenation. This suspension is administered directly into the trachea of the newborn, typically shortly after birth or diagnosis of RDS. By enhancing lung function and preventing alveolar collapse, Beractant helps improve respiratory outcomes in neonates. Its use is crucial in managing respiratory complications, promoting better survival rates, and improving overall health in vulnerable premature infants.
View Complete Details
| Packaging Type | Box |
| Form | Liquid |
| Usage | Prostate Cancer |
| Strength | 32mg |
| Pack Size | 150ml |
| Shelf Life | 24 Months |
32 mg Enzalutamide oral solution is a medication primarily used for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). Enzalutamide functions as an androgen receptor inhibitor, blocking the effects of male hormones like testosterone that stimulate cancer cell growth. This solution form allows for flexible dosing, making it suitable for patients who may have difficulty swallowing capsules. Typically taken once daily, with or without food, it aims to improve survival rates and quality of life. Regular monitoring is essential due to potential side effects, including fatigue, hypertension, and risk of seizures.
View Complete Details
- Developed and Managed by IndiaMART InterMESH Limited










